News Releases

Dr. Philip Schulman Joins eviti’s Hematology-Oncology Medical Office

Home Home > Homepage > Dr. Philip Schulman Joins eviti’s Hematology-Oncology Medical Office
| July 15, 2013 |

Former Chief of Medical Oncology at Memorial Sloan Kettering Cancer Center-Commack, Long Island Joins eviti’s Hematology-Oncology Medical Office

Philadelphia, PA [July 15, 2013] – eviti, Inc. has appointed Dr. Philip Schulman to the position of Medical Director, Hematology-Oncology. As part of the eviti Medical Office team, Dr. Schulman’s responsibilities include reviewing cancer treatment plans for adherence to evidence-based standards and interacting with treating physicians and payers.

Arlene Forastiere, M.D., SVP, Medical Affairs says, “Dr. Schulman is a valuable addition to the eviti team. He brings a great deal of oncology knowledge and experience that will prove beneficial in providing eviti users with clinical decision support.”

In addition to serving on the eviti, Inc. Medical Advisory Board for the past three years, Dr. Schulman held the position of Chief of Medical Oncology at Memorial Sloan Kettering Cancer Center-Commack, Long Island from 2000 until June 2013 and Clinical Member and attending physician in the Division of Medicine. Previously, he was Chief of the Leukemia Service of North Shore University Hospital, Manhasset.

Dr. Schulman graduated from Upstate Medical Center in Syracuse and completed residency training at North Shore University Hospital/Cornell Medical School followed by a fellowship in Hematology-Oncology at Memorial Sloan Kettering Cancer Center. Dr. Schulman is an expert in hematologic malignancies; he has published more than 100 papers and abstracts and presented clinical trials research at national and international oncology meetings.

About eviti, Inc.

eviti, Inc. is a leading health information technology and clinical decision-support company delivering solutions to improve the quality of cancer care and reduce its cost. eviti represents the culmination of almost a decade of experience providing oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.

eviti’s growing national prominence is evidenced by the 2,700+ practices already registered to use the eviti platform. eviti’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind, meticulously compiled from the world’s leading sources. eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies. eviti allows the best cancer care to be available everywhere. For more information, visit www.eviti.com.